Please provide your email address to receive an email when new articles are posted on . Adjuvant chemotherapy with modified FOLFIRINOX resulted in significantly longer survival vs. gemcitabine among ...

Compared with gemcitabine, a modified FOLFIRINOX regimen improved survival rates over five years of follow-up for patients with pancreatic ductal adenocarcinoma who underwent resection, although all ...

Please provide your email address to receive an email when new articles are posted on . Neoadjuvant modified FOLFIRINOX alone vs. with hypofractionated radiotherapy demonstrated favorable OS among ...

Patients with pancreatic cancer who received chemotherapy both before and after surgery experienced longer survival rates than would be expected from surgery followed by chemotherapy, according to a ...

(RTTNews) - Immuneering Corporation (IMRX), a Massachusetts-based biopharmaceutical company Monday announced a positive update from its Phase 2a study of IMM-1-104 combined with modified FOLFIRINOX ...

Patients with pancreatic cancer who received chemotherapy both before and after surgery experienced longer survival rates than would be expected from surgery followed by chemotherapy, according to a ...

In a study of patients with borderline resectable pancreatic cancer, combination chemotherapy with modified FOLFIRINOX before surgery increased survival relative to historical data and compared ...

Cranbury, NJ, May 09, 2017 (GLOBE NEWSWIRE) -- Cranbury, N.J., May 09, 2017 --(GlobeNewswire)-- Cornerstone Pharmaceuticals, Inc., a clinical-stage, oncology-focused pharmaceutical company, today ...

Impact of KRAS mutational status on outcomes in patients with pancreatic cancer (PDAC). This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I. This abstract does not include a full text ...

Although practice patterns vary widely, modified, reduced-dose FOLFIRINOX is as effective as standard, full-dose regimens for patients with metastatic pancreatic cancer in the first-line setting, and ...

CRANBURY, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a company focused on the growing field of cancer metabolism-based therapeutics, today ...